As aromatase catalyzes the biosynthesis of estrogen from androgens, thus the inhibition of aromatase activity has become the standard treatment for hormone-de-pendent breast cancers in women (Eisen et al., 2008[30]). The gene discussed is CYP19A1; the disease is breast cancer.